Effects of green tea on gene expression of hepatic gluconeogenic enzymes in vivo. 2004

Yu Koyama, and Kouichi Abe, and Yukimi Sano, and Yuki Ishizaki, and Marina Njelekela, and Yutaka Shoji, and Yukihiko Hara, and Mamoru Isemura
Laboratory of Cellular Biochemistry, COE Program in the 21st Century, Graduate School of Nutritional and Environmental Sciences, The University of Shizuoka, Shizuoka, Japan.

It has recently been reported that the major green tea polyphenolic constituent, epigallocatechin 3-gallate (EGCG), mimics the cellular effects of insulin including the reductive effect on the gene expression of rate-limiting gluconeogenic enzymes in a cell culture system. We show that administration of green tea that contains EGCG caused a reduction in the level of mRNAs for gluconeogenic enzymes, phosphoenolpyruvate carboxykinase and glucose-6-phosphatase in the mouse liver. EGCG alone was also found to down-regulate the gene expression of these enzymes but not so curcumin or quercetin. The results of this study support the idea that green tea intake may be beneficial in the prevention of diabetes mellitus.

UI MeSH Term Description Entries
D007004 Hypoglycemic Agents Substances which lower blood glucose levels. Antidiabetic,Antidiabetic Agent,Antidiabetic Drug,Antidiabetics,Antihyperglycemic,Antihyperglycemic Agent,Hypoglycemic,Hypoglycemic Agent,Hypoglycemic Drug,Antidiabetic Agents,Antidiabetic Drugs,Antihyperglycemic Agents,Antihyperglycemics,Hypoglycemic Drugs,Hypoglycemic Effect,Hypoglycemic Effects,Hypoglycemics,Agent, Antidiabetic,Agent, Antihyperglycemic,Agent, Hypoglycemic,Agents, Antidiabetic,Agents, Antihyperglycemic,Agents, Hypoglycemic,Drug, Antidiabetic,Drug, Hypoglycemic,Drugs, Antidiabetic,Drugs, Hypoglycemic,Effect, Hypoglycemic,Effects, Hypoglycemic
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D008297 Male Males
D008517 Phytotherapy Use of plants or herbs to treat diseases or to alleviate pain. Herb Therapy,Herbal Therapy
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D010936 Plant Extracts Concentrated pharmaceutical preparations of plants obtained by removing active constituents with a suitable solvent, which is evaporated away, and adjusting the residue to a prescribed standard. Herbal Medicines,Plant Extract,Extract, Plant,Extracts, Plant,Medicines, Herbal
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D002392 Catechin An antioxidant flavonoid, occurring especially in woody plants as both (+)-catechin and (-)-epicatechin (cis) forms. Catechinic Acid,Catechuic Acid,(+)-Catechin,(+)-Cyanidanol,(+)-Cyanidanol-3,(-)-Epicatechin,(2R,3R)-2-(3,4-Dihydroxyphenyl)-3,5,7-chromanetriol,2H-1-Benzopyran-3,5,7-triol, 2-(3,4-dihydroxyphenyl)-3,4-dihydro-, (2R-cis)-,3,3',4',5,7-Flavanpentol,Catergen,Cianidanol,Cyanidanol-3,Epicatechin,KB-53,Z 7300,Zyma,Cyanidanol 3,KB 53,KB53
D003920 Diabetes Mellitus A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response

Related Publications

Yu Koyama, and Kouichi Abe, and Yukimi Sano, and Yuki Ishizaki, and Marina Njelekela, and Yutaka Shoji, and Yukihiko Hara, and Mamoru Isemura
February 2009, Biomedical research (Tokyo, Japan),
Yu Koyama, and Kouichi Abe, and Yukimi Sano, and Yuki Ishizaki, and Marina Njelekela, and Yutaka Shoji, and Yukihiko Hara, and Mamoru Isemura
June 2010, Biomedical research (Tokyo, Japan),
Yu Koyama, and Kouichi Abe, and Yukimi Sano, and Yuki Ishizaki, and Marina Njelekela, and Yutaka Shoji, and Yukihiko Hara, and Mamoru Isemura
June 2011, The Journal of toxicological sciences,
Yu Koyama, and Kouichi Abe, and Yukimi Sano, and Yuki Ishizaki, and Marina Njelekela, and Yutaka Shoji, and Yukihiko Hara, and Mamoru Isemura
April 2011, Biomedical research (Tokyo, Japan),
Yu Koyama, and Kouichi Abe, and Yukimi Sano, and Yuki Ishizaki, and Marina Njelekela, and Yutaka Shoji, and Yukihiko Hara, and Mamoru Isemura
September 2011, Journal of medicinal food,
Yu Koyama, and Kouichi Abe, and Yukimi Sano, and Yuki Ishizaki, and Marina Njelekela, and Yutaka Shoji, and Yukihiko Hara, and Mamoru Isemura
March 2012, Journal of the science of food and agriculture,
Yu Koyama, and Kouichi Abe, and Yukimi Sano, and Yuki Ishizaki, and Marina Njelekela, and Yutaka Shoji, and Yukihiko Hara, and Mamoru Isemura
January 1980, Substance and alcohol actions/misuse,
Yu Koyama, and Kouichi Abe, and Yukimi Sano, and Yuki Ishizaki, and Marina Njelekela, and Yutaka Shoji, and Yukihiko Hara, and Mamoru Isemura
February 1974, Biochemical pharmacology,
Yu Koyama, and Kouichi Abe, and Yukimi Sano, and Yuki Ishizaki, and Marina Njelekela, and Yutaka Shoji, and Yukihiko Hara, and Mamoru Isemura
January 1986, Annals of the New York Academy of Sciences,
Yu Koyama, and Kouichi Abe, and Yukimi Sano, and Yuki Ishizaki, and Marina Njelekela, and Yutaka Shoji, and Yukihiko Hara, and Mamoru Isemura
June 2005, Journal of dairy science,
Copied contents to your clipboard!